ABSTRACT Introduction: Actinic cystitis (AC) is the manifestation of symptoms and signs following pelvic radiotherapy. Pelvic radiotherapy produces both acute and chronic damage and such damage may have a devastating impact on the quality and on the amount of life of the patient. Objectives: To evaluate the number of radical cystectomies that have become necessary in the last five years in our department for AC after radiation treatment.
Introduction
Actinic cystitis (AC) is the manifestation of symptoms and signs such as haematuria, pain during urination, chronic pelvic pain, or clinical-pathological situations such as incontinence, hydronephrosis in impaired bladder capacity and renal failure following pelvic radiotherapy.
Pelvic radiotherapy produces both acute and chronic damage, which may have a devastating impact on the quality of life of the patient.
Of patients with AC, 5%-10% are subjected to radiotherapy (1, 2) .
Clinical symptoms and signs such as haematuria, pain during urination, chronic pelvic pain, could appear up to 15 years after radiotherapy treatment (3) .
The pathophysiology can be divided into three distinct phases:
1) a short acute phase that lasts until a few weeks after radiotherapy; 2) a symptom-free phase, physical well-being; 3) an irreversible phase, characterised by a late chronic damage (4).
High-dose radiant energy can cause cell death directly by destroying cell membranes and DNA sequences, or indirectly through the formation of high levels of free radicals from the H2O molecule radiolysis. The first symptoms are due to acute lesions of the outer urothelial transitional cell layers, which have a reduced cell turnover and increased susceptibility to radiation damage.
Exposure of the damaged transitional layer to urine perpetuates the inflammatory mechanism (5). In the phase of physical well-being, a chronic subclinical inflammation developed.
Late radiation damage is based on a progressive ischaemia of microscopical blood vessels with development of obliterative micro arteritis. This leads to tissue atrophy, deposition of collagen, fibroblast infiltration, decreased cellular muscle relaxation, development of tissue edema and massive fibrosis (1) .
When patients are in the late-onset phase, therapy is complex and often recovery is not complete.
Types of therapies

Hyperidratation and continuous bladder irrigation
Turkeri et al (6) reported that continuous bladder irrigation significantly decreased the frequency of haemorrhagic cystitis (HC) in patients receiving chemotherapy with cyclophosphamide for bone marrow transplant compared with no bladder irrigation (23% vs. 53%, respectively; p<0.004). Is very important that all clots are removed before starting continuous bladder irrigation (6) .
Chondroitin sulphate
Hazewinkel et al (7) hypothesised that instillation of chondroitin sulphate in patients undergoing radiotherapy for gynaecological cancer may limit the risk of radiation therapy (RT) cystitis symptoms. The efficacy of chondroitin sulphate was tested in 20 patients; 10 received weekly intravesical installations and 10 received no therapy. The tolerability of instillations and bladder pain were evaluated using a visual analogue scale (VAS). Patients receiving chondroitin sulphate reported less troublesome symptoms and pain; treatment with chondroitin sulphate was well tolerated (7).
Sodium hyaluronate
Sodium hyaluronate, a derivative of hyaluronic acid, has been developed to restore the glycosaminoglycan layer of the bladder surface. Sodium hyaluronate was successfully used in the treatment of refractory interstitial cystitis. More recently, it has been used in preventing and treating chemical-and radiotherapy-induced cystitis (8) (9) (10) .
Data from a retrospective study by Delgado et al (11) , which assessed toxicity using the Radiation Therapy Oncology Group (RTOG)/European Organisation for the Research and Treatment of Cancer (EORTC) Radiation Toxicity Score show that weekly instillations of sodium hyaluronate in patients receiving RT for gynaecological tumours decreased radiotherapy-induced toxicity (11) .
Further data from a prospective study by Sommariva et al (12) show that sodium hyaluronate also relieves the symptoms of chemo-or radiation-induced cystitis. In 69 consecutive patients with symptoms of cystitis after radiotherapy for prostate cancer or after intravesical Bacillus Calmette-Guerin (BCG) or mitomycin C for bladder cancer were given intravesical instillations of sodium hyaluronate and cortisone. Sixty-seven (97%) patients reported complete relief of dysuria and pain, which was assessed using a VAS (12) .
Prostaglandin
Data from a case series suggest that intravesical prostaglandins (PGE1 PGE2, and PGF2α) may be useful to prevent or treat HC secondary to RT or cyclophosphamide therapy. Although the exact mechanism of action is unclear, the prostaglandins may work by causing smooth muscle contraction of the blood vessels in the mucosa and submucosa. The second hypothesis is that prostaglandins stimulate platelet aggregation and then haemostasis (13) .
Formalin
Intravesical formalin installation has been evaluated for the treatment of HC secondary to RT-induced cystitis. It is effective in controlling severe bladder haemorrhage after RT of the pelvis, but it may cause major complications such as bladder perforation, bladder fistula, pelvic fibrosis (14) .
Alum irrigation
Alum irrigation is useful in the management of RT-induced HC with varying degrees of success, but there are some case reports of aluminium poisoning after intravesical alum irrigation (15, 16) .
Systemic treatments
Systemic treatments, e.g., HBO, oestrogen, sodium pentosan polysulfate, recombinant factor VII or VIII, and aminocaproic acid have been used with some success in the treatment of HC (17) .
Several small series and case reports have reported that HC secondary to RT or cyclophosphamide therapy has been successfully treated with oestrogen (18) .
Sodium pentosan polysulfate is a semi-synthetic glycosaminoglycan (GAG) similar to heparin with anticoagulant properties and fibrinolytic effects. This treatment was successful in small series and case reports in treating patients who have developed HC secondary to RT (19) (20) (21) (22) .
In a larger study, Sandhu et al (23) retrospectively reviewed the pharmacy records of 53 patients with HC after RT for pelvic malignancy. The treatment was successful in 10 patients because the haematuria stopped completely (23).
Karimi reported a potential role for recombinant factor VII in the treatment of cyclophosphamide-and RT-induced HC (24) .
Aminocaproic acid has proven to be successful in one small study of patients with intractable bladder haemorrhages, most of whom had RT-or cyclophosphamide-induced cystitis. There were no side effects reported (25) .
Clot evacuation and endoscopic fulguration
Bladder outlet obstruction from clots can lead to bladder rupture and infections. Clot removal is performed by placing a wide-lumen bladder catheter followed by bladder irrigation with sodium chloride solution. If haematuria persists, continuous bladder irrigation can be started through a three-way catheter. All clots must be removed before starting continuous irrigation to avoid catheter malfunctioning and consequent bladder overdistension or bladder breaking. If clot evacuation remains unsuccessful, or haematuria persists, the patient should undergo cystoscopy with clot evacuation and fulguration of bleeding points. Cystoscopy with fulguration of bleeding points is a very effective method of treating HC that is unresponsive to conservative measures. There are some methods of fulguration that include the use of electrocoagulation and several types of lasers. Potential morbidity following cystoscopy with fulguration includes bladder perforation with subsequent fistula formation and the reduction of bladder capacity caused by scar fibrosis (26) .
Hyperbaric therapy
Hyperbaric oxygen therapy (HBOT) has been used in case studies for the management of HC. The hyperbaric oxygen chamber provides conditions where haemoglobin is completely saturated and oxygen is dissolved at very high levels in the blood plasma, providing therapeutic benefits. This kind of therapy promotes angiogenesis and the healing process in radiated tissue (27) .
Surgery
AC is often associated with prolonged hospitalization and significant morbidity. It may require aggressive measures such as radical surgery like cystectomy and urinary diversion. This is successful to stop haematuria and reduces chronic pelvic pain (28) .
We bring our experience in a high-volume centre (over 35 cystectomies/year).
Objectives
To evaluate the number of radical cystectomies that have become necessary in the last five years in our department for AC after radiation treatment.
To evaluate the characteristics of the patients and, in particular, the type of primitive cancer, the radiation dose used during radiotherapy, the time between radiotherapy and cystectomy, and the motivation that required the surgery.
Materials and methods
From February 2012 to February 2017, 11 patients underwent "open" cystectomy for AC.
All patients were studied with radiographic examinations (cystogram and contrast-CT scan of abdomen) and endoscopy prior to surgery.
We retrospectively evaluated the kind of primitive cancer, the radiation dose administered, the time between radiation treatment and cystectomy.
We also studied the related symptoms that required surgery.
To define symptomatology, we defined haemorrhagic haematuria as the haematuria that required the administration of more than two blood transfusions (with haemoglobin values ≤8 g/dL). We defined incontinence as the use of more than one diaper a day. We defined kidney failure as the situation when glomerular filtration rate is below 60 mL/min.
Chronic pelvic pain was evaluated by an anaesthesiologist according to the multidimensional scale Brief Pain Questionnaire (29) .
The data were collected at our hospital.
Results
There were 11 patients, 8 males and 3 females. The mean age at the time of cystectomy was 75 years. In 6 patients (54.4%) radiotherapy was performed for prostate cancer, in 2 patients (18.1%) for rectal cancer, in 3 patients (27.2%) for endometrial cancer.
Total radiation dose was different in different patients, and depended on different types and localization of the cancer. In detail, the 6 patients with prostate cancer underwent radiotherapy with a median dose of 63 Gy (60-70 Gy). Patients with rectal cancer were treated with 50 Gy. In the 3 patients with endometrial cancer the radiotherapy dose was of 46 Gy/patient.
The median time between radiotherapy and cystectomy was 111 months (24-256 months).
All patients had symptoms before surgery. Ten patients (90.9%) experienced gross haematuria. Nine had anaemia. Seven patients (63.3%) suffered of chronic pelvic pain, 6 (54.5%) patients were incontinent, 6 patients (54.5%) presented kidney failure. Three patients (27.2%) suffered of coloproctitis. One patient developed urethral stenosis after radiotherapy.
All patients were treated with hyperidratation and continuous bladder irrigation. Nine patients (81%) with alum irrigation, two (18%) with sodium hyaluronate, seven (63.3%) with gross haematuria were treated with endoscopic clot evacuation and fulguration.
Two patients (18.1%) were endoscopically treated for non-muscle invasive bladder cancer in the year before cystectomy. One patient was treated with intravesical irrigation of BCG.
After surgery, patients underwent regular outpatient follow-up, experiencing the disappearance of painful symptoms and haematuria. There was also an improvement in kidney function in patients with hydroureteronephrosis before cystectomy.
Discussion
The first approach to patients with AC is often supportive care. Supportive or conservative therapy include: hyperhydration and continuous bladder irrigation with physiological solution, chondroitin sulfate, sodium hyaluronate, sodium pentosan polysulfate prostaglandins, formalin, alum irrigation; systemic treatments such as hyperbaric oxygen therapy, oestrogen administration, coagulation factors (VII or VIII) and aminocaproic acid; endoscopic therapy with evacuation of clots and fulguration.
Surgery remains the most invasive treatment in the management of those patients who are not responsive to these treatments.
Surgery is reserved for the management of severe symptoms and complications that do not respond to medical management. Indications for surgery include the following: gross haematuria that does not respond to bladder irrigation or that requires numerous transfusions; small and contracted bladder with incontinence or severe frequency of urination; specific complications of radiation (fistulas, hydronephrosis, strictures). Surgical options for small-volume bladder include bladder augmentation, urinary diversion, and cystectomy. Although AC is a potentially severe complication, which can cause significant morbidity and considerable expense due to prolonged hospitalisation, there is no published national or international consensus on the optimal therapeutic strategy. The evidence base is currently limited for the various treatment methods used to prevent and/or treat AC. Most of the reported studies are either uncontrolled, non-randomised studies, or small case series or case reports, and involve few patients who have had several different treatment methods.
